The Effectiveness of Neurodynamic Mobilization in Carpal Tunnel Syndrome

January 13, 2026 updated by: Merve Akdeniz Leblebicier, Kutahya Health Sciences University

The Effectiveness of Neurodynamic Nerve Mobilization in Addition to Physical Therapy on the Median Nerve and Abductor Pollicis Brevis Muscle in Patients With Mild and Moderate Carpal Tunnel Syndrome

This randomized, clinical, single-blinded, controlled study will initially planned to include 86 patients diagnosed with carpal tunnel syndrome who applied to Kütahya Health Sciences University, Evliya Çelebi Training and Research Hospital, Physical Medicine and Rehabilitation outpatient clinic and Kutahya City Hospital.Patients aged 20-55 years who were diagnosed with mild and moderate carpal tunnel syndrome by electromyography (EMG) in the last 6 months were included in the study. The patients were randomized into two groups using the computer-assisted randomization method. Median nerve mobilization and ultrasound therapy will be given to the study group, and only ultrasound therapy will be given to the control group. All the patients were evaluated with the Visual Analog Scale (VAS), Hand and Pinching Grip Test, Boston Carpal Tunnel Questionnaire (BCTQ) and Median Nerve and Abductor Pollicis Brevis Muscle ultrasonography before the intervention and at the third week of intervention.

Study Overview

Study Type

Interventional

Enrollment (Actual)

86

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Turkey
      • Kütahya, Turkey, Turkey (Türkiye), 43050
        • Kutahya Health Sciences University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Diagnosed with mild-to-moderate CTS on the dominant hand, based on the electrodiagnostic examination.
  • Aged 20-55 years.
  • Consent to receive the described treatment.
  • Lasting symptoms at least 3 months

Exclusion Criteria:

  • A systemic inflammatory disease.
  • Any disease that can cause polyneuropathy, for example, diabetes mellitus.
  • A cognitive disorder.
  • Receiving psychotherapy.
  • A pacemaker.
  • Any disease that can affect the central nervous system.
  • Carpal tunnel syndrome surgery history

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Median nerve mobilization in addition to ultrasound therapy
In addition nerve mobilization, ultrasound therapy will be applied to all patient in experimental group via methods explained below.

Passive neuromobilisation of the median nerve and functional self-exercises. The procedure started with the patient in the supine position. The following steps were taken in sequence: shoulder girdle depression; slight abduction of the elbow extension with arm lateral rotation and forearm supination; wrist, finger and thumb extensions were added; and the shoulder was taken into further extension.

To apply maximum stretch opposite cervical side flexion was done, and, in the end, the wrist was repeatedly moved into and out of stretch by performing a few degrees of flexion and extension at the wrist.

This mobilization technique will be performed by an experienced physician/physiotherapist three times a week for 3 weeks, and the patients will be given 3 sets of 15 cycles with a 1-minute rest period in each set.

In control group, patients will received only ultrasound therapy. The patient will be in a sitting position with his/her face facing the physiotherapy technician, elbow in 90 degree flexion, forearm in supination, wrist in neutral position and supported by placing a towel under the patient's extremity and will be applied in Us intermittent mode with an intensity of 0.8 W/cm2 in 1 MHZ frequency in 1:4 mode for 10 minutes, moving in a way to draw an infinity sign for 10 seconds. Treatment will be given 5 days a week for 3 weeks and a total of 15 sessions.
Active Comparator: Ultrasound therapy
In control group, patients will received only ultrasound therapy.
In control group, patients will received only ultrasound therapy. The patient will be in a sitting position with his/her face facing the physiotherapy technician, elbow in 90 degree flexion, forearm in supination, wrist in neutral position and supported by placing a towel under the patient's extremity and will be applied in Us intermittent mode with an intensity of 0.8 W/cm2 in 1 MHZ frequency in 1:4 mode for 10 minutes, moving in a way to draw an infinity sign for 10 seconds. Treatment will be given 5 days a week for 3 weeks and a total of 15 sessions.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Ultrasound assessment
Time Frame: Change from Baseline at 3th weeks

The Median nerve's diameter will be evaluated bilaterally by another researcher blinded to interventions and experienced in musculoskeletal ultrasonography, using ultrasound with a 6-18 Mhz linear probe (Mindray-UMT 200, USA).

During the examination, patients will be seated on a stretcher, while the examiner sat on a higher stool.

The Median nerve will be evaluated by measuring the circumference of the nerve at the location where the nerve entered the carpal tunnel.

The ultrasound probe will be positioned above the epicondylus lateralis. The nerve cross-sectional area (CSA) will be recorded in the carpal tunnel while it was perpendicular to the wrist at 90 degrees on the Median nerve trace.

The nerve diameter will be measured from the circumference of the epineurium.

Change from Baseline at 3th weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hand and pinching grip measurement
Time Frame: Change from Baseline at 3th weeks

The grip strength of the hand is measured with the Jamar hand dynamometer recommended by the American Association of Hand Therapists (AETD).

The measurement will be performed in the standard position specified by the AETD; the patient will be seated, shoulders in adduction and neutral rotation, elbow in 90 degree flexion, forearm in mid-rotation and supported, wrist in neutral position with three repetitions and the results will be recorded in kilograms.

Pinch force will be measured in the same position as the hand grip strength is measured with a pincmeter.

It will be evaluated in two different positions, lateral and triple grip. When evaluating the lateral grip, the patient will be asked to press the pinchmeter from the top with the middle of the distal phalanx of the thumb and support the lower part of the pinchmeter with the second phalanx of the index finger.

When evaluating the triple grip, measurements will be made by squeezing the thumb on one side of the pinchmeter an

Change from Baseline at 3th weeks
Symptom severity and functional status
Time Frame: Change from Baseline at 3th weeks

Symptom severity and functional status were evaluated with BCTQ, a self-report measure of CTS with two domains: the Boston Carpal Tunnel Syndrome Questionnaire Symptom severity scale comprising 11 items to evaluate pain, paresthesia, and weakness and the Boston Carpal Tunnel Syndrome Questionnaire Symptom functional status domain with eight items assessing the ability to perform hand-related activities.

For each item, a high score indicates an increasing severity of symptoms or difficulty experienced.

The validity and reliability analyses of the Turkish version of BCTQ were undertaken by Sezgin et al19 Reliability of the Turkish version was very good, with high internal consistency (Cronbach's alpha 0.82 for symptom severity scale, and 0.88 for functional status scale), and reproducibility (Pearson correlation coefficient 0.60 for symptom severity scale, and 0.77 for functional status scale).

Change from Baseline at 3th weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Merve Akdeniz Leblebicier, MD, Kutahya Health Sciences University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 15, 2025

Primary Completion (Actual)

June 15, 2025

Study Completion (Actual)

August 15, 2025

Study Registration Dates

First Submitted

March 12, 2025

First Submitted That Met QC Criteria

March 12, 2025

First Posted (Actual)

March 18, 2025

Study Record Updates

Last Update Posted (Actual)

January 15, 2026

Last Update Submitted That Met QC Criteria

January 13, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Carpal Tunnel Syndrome (CTS)

Clinical Trials on Median Nerve Mobilization

Subscribe